April 30, 2025 03:42 PM EDT

BeiGene scores a win from US Patent Office in spat over Brukinsa

Nicole DeFeudis

Editor

A tribunal within the US Patent and Trademark Office invalidated several claims of a patent held by AbbVie’s Pharmacyclics, marking a key win for its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BeiGene scores a win from US Patent Office in spat over Brukinsa

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Exits continue at FDA, as more staff in drug office follow fired colleagues out the door

Updated: Novartis to buy Regulus Therapeutics for up to $1.7B

FDA approves J&J's rare disease drug that's expected to compete with argenx and UCB

Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments

The Endpoints Slack interview: Arc Institute's Patrick Hsu on investing, AI and new ways of research

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

BeiGene scores a win from US Patent Of­fice in spat over Brukin­sa

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

BeiGene scores a win from US Patent Office in spat over Brukinsa